Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Bm_squib
CORGARD H.S. TABLETS CORGARD TABLETS SCHEDULING STATUS: S3 PROPRIETARY NAME (and dosage form) CORGARD H.S. TABLETS CORGARD TABLETS COMPOSITION CORGARD H.S. tablets contain 40 mg of nadolol and CORGARD tablets contain 80 mg of nadolol, chemically known as 2,3Cis-1,2,3,4-tetrahydro-5[2-hydroxy-3-(tert-butyl-amino) propoxy]-2,3-naphthalenediol. PHARMACOLOGICAL CLASSIFICATION Category A5.2 - Adrenolytics (Sympatholytics). PHARMACOLOGICAL ACTION Nadolol specifically competes with beta-adrenergic receptor agonists for available beta receptor sites. When access to beta receptor sites is blocked by nadolol, the chronotropic, inotropic and vasodilator responses to beta-adrenergic stimulation are decreased proportionally. Absorption of nadolol after oral dosing is variable averaging about 30%. Peak serum concentrations usually occur 3 to 4 hours after administration of medication. Nadolol is not metabolized, and is excreted unchanged. The absorption of nadolol is not affected by food intake. The serum half-life of therapeutic doses of nadolol is relatively long and usually ranges from 20 to 24 hours. Because nadolol is excreted predominantly in the urine its half life increases in the presence of renal impairment. Approximately 30% of the nadolol present in serum is reversibly bound to plasma protein. Steady-state serum concentrations of nadolol are attained in six to nine days with once-daily dosage in persons with normal renal function. No consistent correlation between dose or plasma concentration and therapeutic effect has yet been established, and the observed dose-response range is wide. This may be because sympathetic tone varies widely between individuals. Because of the lack of any reliable test to estimate sympathetic tone, proper dosage requires titration. Corgard has low lipophilicity as de Read the complete document